Iterum Therapeutics plc (ITRM)
- Previous Close
1.7700 - Open
1.8000 - Bid 1.7200 x 100
- Ask 1.8300 x 100
- Day's Range
1.6900 - 1.8100 - 52 Week Range
0.8080 - 2.5000 - Volume
515,613 - Avg. Volume
2,469,626 - Market Cap (intraday)
48.843M - Beta (5Y Monthly) 2.25
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7600 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.50
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
www.iterumtx.comRecent News: ITRM
View MorePerformance Overview: ITRM
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ITRM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ITRM
View MoreValuation Measures
Market Cap
48.70M
Enterprise Value
56.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.35%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-28.34M
Diluted EPS (ttm)
-1.7600
Balance Sheet and Cash Flow
Total Cash (mrq)
11.72M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-28.46M